Patents Issued in June 14, 2018
  • COMPOUNDS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
    Publication number: 20180161310
    Abstract: Compounds that inhibit synaptic hyperexcitability, pharmaceutical compositions of these compounds, and methods of using the compounds and pharmaceutical compositions thereof to treat diseases and/or disorders such as epilepsy, neuropathic pain, spinal cord injury spasticity, morphine-induced hyperalgesia, schizophrenia, and autism spectrum disorders are disclosed.
    Type: Application
    Filed: December 7, 2017
    Publication date: June 14, 2018
    Inventors: Randall T. Peterson, David Kokel, Tama Evron, Andrea Velenich
  • SYNTHETIC TRITERPENOIDS AND METHODS OF USE IN THE TREATMENT OF DISEASE
    Publication number: 20180161311
    Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.
    Type: Application
    Filed: August 14, 2017
    Publication date: June 14, 2018
    Applicants: REATA PHARMACEUTICALS, INC., TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Michael B. SPORN, Karen T. LIBY, Gordon W. GRIBBLE, Tadashi HONDA, Robert M. Kral, Colin J. MEYER
  • SUBSTITUTED IMIDAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS
    Publication number: 20180161312
    Abstract: Disclosed are compounds, compositions and methods for treating various diseases, syndromes, conditions and disorders, including pain. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, and G are defined herein.
    Type: Application
    Filed: February 9, 2018
    Publication date: June 14, 2018
    Inventors: Ishtiyaque Ahmad, Rajagopal Bakthavatchalam, Sivaramakrishna Battula, Henricus Jacobus Maria Gijsen, Saravanan Vadivelu, Mark Wall, Christopher Flores
  • Inhibitors of Mcl-1 as Drugs to Overcome Resistance to BRAF Inhibitors and MEK Inhibitors
    Publication number: 20180161313
    Abstract: The present invention includes compositions and methods for inhibiting MCL-1, including novel inhibitors of MCL-1, and compositions and methods for treating a subject with cancer that is refractory to one or more MAPK pathway protein inhibitors.
    Type: Application
    Filed: June 6, 2016
    Publication date: June 14, 2018
    Inventors: Sanjay K. Srivastava, Neel M. Fofaria
  • Methods for Treating Hyperuricemia and Related Diseases
    Publication number: 20180161314
    Abstract: Provided herein are methods of treating gout, treating hyperuricemia, lowering serum uric acid, or the like with compounds of formula (I) have the following structure Further, provided herein are compositions comprising a compound of formula (I).
    Type: Application
    Filed: February 8, 2018
    Publication date: June 14, 2018
    Inventor: Barry D. Quart
  • TREATMENT METHODS UTILIZING STEM CELL MOBILIZERS AND IMMUNOSUPPRESSIVE AGENTS
    Publication number: 20180161315
    Abstract: The present invention relates to the field of organ transplantation. In one aspect, the present invention provides methods of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of a stem cell mobilizer and an immunosuppressive agent. In particular embodiments, the present invention provides a method of treating an organ transplant recipient comprising administering to the recipient a therapeutically effective amount of an agent that mobilizes CD34+ and/or CD133+ stem cells and a low dose of an immunosuppressive agent.
    Type: Application
    Filed: December 10, 2010
    Publication date: June 14, 2018
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Zhaoli Sun, George Melville Williams
  • 2-(AZAINDOL-2-YL) BENZIMIDAZOLES AS PAD4 INHIBITORS
    Publication number: 20180161316
    Abstract: Compounds of formula (I) wherein; R1 is hydrogen or C1-6alkyl; R2 is hydrogen, C1-6alkyl, perhalomethylC0-5alkyl-O—, or C1-6alkoxy; R3 is hydrogen, C1-6alkyl, or C1-6alkoxyC1-6alkyl; R4 is hydrogen, C1-6alkyl, perhalomethylC1-6alkyl; or unsubstituted C3-6cycloalkylC1-6alkyl; A is C—R5 or N; B is C—R6 or N; D is C—R7 or N; with the proviso that at least one of A, B, and D, is N; R5 is hydrogen or C1-6alkyl; R6 is hydrogen or C1-6alkyl; R7 is hydrogen, C1-6alkyl, C1-6alkoxy, or hydroxy; R8 is hydrogen or C1-6alkyl, with the proviso that one of R4 and R8 is hydrogen; R9 is hydrogen or hydroxy; R1o is hydrogen or C1-6alkyl; and salts thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosis, and psoriasis.
    Type: Application
    Filed: November 20, 2017
    Publication date: June 14, 2018
    Inventors: Stephen John Atkinson, Michael David Barker, Matthew Campbell, Hawa Diallo, Clement Douault, Neil Stuart Garton, John Liddle, Robert John Sheppard, Ann Louise Walker, Christopher Wellaway, David Matthew Wilson
  • MESYLIC ACID SALT OF ACYLTHIOUREA COMPOUND, CRYSTAL OF THE SAME, AND PROCESS FOR PRODUCING THESE
    Publication number: 20180161317
    Abstract: An object of the present invention is to provide a salt compound of 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide, which is useful as an antitumor agent, and crystal of the salt. The salt and the crystal are excellent in terms of solubility, stability, and peroral absorbability and can be mass-produced. The present invention relates to: a mesylic acid salt of 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide; and the mesylic acid salt including a crystal which gives an X-ray powder diffraction spectrum having characteristic peaks at specific diffraction angles.
    Type: Application
    Filed: April 28, 2016
    Publication date: June 14, 2018
    Applicant: Taiho Pharmaceutical Co., Ltd.
    Inventor: Ayako SATO
  • PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING OBESITY OR LIVER DISEASES, CONTAING TLR7 AGONIST
    Publication number: 20180161318
    Abstract: The present invention is based on the fact that imiquimod, which is a substance that enhances Toll-like receptor 7 (TLR7) related to the innate immunity of a living body, is effective in the prevention and treatment of obesity or liver disease, and the present invention relates to a pharmaceutical composition for the prevention and treatment of obesity or liver disease, wherein the TLR7 agonist used for the immune system disease inhibits fatty acid synthetase (FAS), activates autophagosome or inhibits IGF-1.
    Type: Application
    Filed: May 4, 2016
    Publication date: June 14, 2018
    Applicants: KNOTUS CO., LTD., KNOTUS LIFE SCIENCE INC.
    Inventors: Do Hyeong KIM, Sok Ho KIM, Jung Kee KWON
  • METHODS OF ENHANCING IMMUNE RESPONSE
    Publication number: 20180161319
    Abstract: The present invention relates to a method of enhancing immune response in a subject.
    Type: Application
    Filed: November 22, 2017
    Publication date: June 14, 2018
    Inventors: Joan Mannick, Melody Morris
  • INTRANASAL NALOXONE COMPOSITIONS AND METHODS OF MAKING AND USING SAME
    Publication number: 20180161320
    Abstract: Disclosed herein are compositions containing an opioid antagonist such as naloxone and one or more pharmaceutically acceptable excipients. The compositions may be used for intranasal delivery of Naloxone for the treatment of, for example, opioid overdose in an individual in need thereof. Also disclosed are methods of making compositions containing Naloxone, and devices for nasal delivery of naloxone compositions.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 14, 2018
    Inventors: Joseph Wyse, Michael Paul DeHart
  • Therapeutic Uses of Compounds Having Combined SERT, 5-HT3 and 5-HT1A Activity
    Publication number: 20180161321
    Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.
    Type: Application
    Filed: July 27, 2017
    Publication date: June 14, 2018
    Inventors: Nicholas Moore, Marianne Dragheim, Aneil Batra, Jin Chon
  • PHARMACEUTICAL COMPOSITION
    Publication number: 20180161322
    Abstract: A preparation for oral administration comprising: a pregelatinized starch comprising N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1?R,2?S,3?R,4?S)-2,3-bicyclo[2,2,1]-heptanedicarboxyimide hydrochloride (lurasidone) represented by the formula (1) as an active ingredient; a water-soluble excipient; and a water-soluble polymeric binder, the preparation exhibiting an invariant level of elution behavior even when the content of its active ingredient is varied.
    Type: Application
    Filed: February 6, 2018
    Publication date: June 14, 2018
    Applicant: SUMITOMO DAINIPPON PHARMA CO., LTD.
    Inventor: Kazuyuki FUJIHARA
  • TRAZODONE AND TRAZODONE HYDROCHLORIDE IN PURIFIED FORM
    Publication number: 20180161323
    Abstract: A process of production of trazodone or trazodone hydrochloride that comprises: (a) preparing an organic phase comprising trazodone in at least one organic solvent; (b) preparing an aqueous phase comprising at least one basic compound; (c) mixing said aqueous phase with said organic phase; (d) heating at a temperature of at least 40° C. for at least 30 minutes; (e) recovering said trazodone; and, optionally, (f) treating said trazodone with hydrochloric acid to obtain trazodone hydrochloride. Trazodone or trazodone hydrochloride comprising less than 15 ppm of alkylating substances, and a pharmaceutical composition comprising said trazodone hydrochloride.
    Type: Application
    Filed: February 7, 2018
    Publication date: June 14, 2018
    Applicant: AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A.
    Inventors: Marcello MARCHETTI, Tommaso IACOANGELI, Giovanni Battista CIOTTOLI, Giuseppe BIONDI
  • SHIP1 MODULATORS AND METHODS RELATED THERETO
    Publication number: 20180161324
    Abstract: Compounds of formula (I): where n, R1, R4a, R4b, R5, R7 and R8 are defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
    Type: Application
    Filed: January 30, 2018
    Publication date: June 14, 2018
    Inventors: Lloyd F. Mackenzie, Thomas B. MacRury, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew, Vladimir Khlebnikov, Rudong Shan
  • PHARMACEUTICAL FORMULATION CONTAINING TADALAFIL
    Publication number: 20180161325
    Abstract: Disclosed herein are pharmaceutical compositions comprising Tadalafil, or a salt, or derivatives thereof and pharmaceutical excipients, processes for the preparation thereof, and pharmaceutical compositions containing them. The pharmaceutical compositions have improved physicochemical properties that provide faster onset of action for the treatment of erectile dysfunction.
    Type: Application
    Filed: November 30, 2017
    Publication date: June 14, 2018
    Inventors: Betti SZABÓNÉ ORDASI, Tamás JORDÁN, Richárd Balázs KÁRPÁTI, Andrea UJHELYI, Tamás SOLYMOSI, Hristos GLAVINAS, Genovéva FILIPCSEI
  • PAC-1 COMBINATION THERAPY
    Publication number: 20180161326
    Abstract: The invention provides compositions and methods for the induction of cancer cell death. The compositions and methods of using them include use of compositions in therapy for the treatment of cancer and for the selective induction of apoptosis in cancer cells. The drug combinations described herein can be synergistic and can have lower neurotoxicity effects than the same amounts of other compounds and combinations of compounds, and can be effective when a particular cancer has become resistant to previously administered therapies.
    Type: Application
    Filed: June 6, 2016
    Publication date: June 14, 2018
    Applicant: The Board of Trustees of the University of lllinois
    Inventors: Paul J. HERGENROTHER, Jessie PEH
  • ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3
    Publication number: 20180161327
    Abstract: The present invention relates to the treatment or prevention of skeletal disorders, in particular skeletal diseases, developed by patients that display abnormal increased activation of the fibroblast growth factor receptor 3 (FGFR3), in particular by expression of a constitutively activated mutant of FGFR3.
    Type: Application
    Filed: January 16, 2018
    Publication date: June 14, 2018
    Inventors: Laurence LEGEAI-MALLET, Arnold MUNNICH, Patricia BUSCA, Florent BARBAULT
  • TREATMENT OF CANCER AND BENIGN PROLIFERATIVE DISORDERS
    Publication number: 20180161328
    Abstract: Disclosed herein are compositions comprising lopinavir alone or in combination with ritonavir for use as a medicament in the treatment of cancer or benign proliferative disorders (warts) or in the prevention of the development of cancer. Pharmaceutical compositions formulated for topical application comprising a therapeutically effective amount of lopinavir or a therapeutically effective amount lopinavir and ritonavir in a pharmaceutically acceptable vehicle are also provided. Also disclosed are methods of treating a patient having an HPV related dysplasia of the cervix comprising administering to said patient a therapeutically effective dose of the disclosed pharmaceutical compositions.
    Type: Application
    Filed: September 5, 2017
    Publication date: June 14, 2018
    Applicant: The University of Manchester
    Inventors: Ian Hampson, Lynne Hampson
  • PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20180161329
    Abstract: The purpose of the present invention is to provide a compound having an excellent CDK4/6 inhibiting activity. The present invention is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 27, 2016
    Publication date: June 14, 2018
    Applicant: Teijin Pharma Limited
    Inventors: Tsuyoshi MIZUNO, Tomohiro SHIMADA, Gen UNOKI, Masaru EBISAWA, Susumu TAKEUCHI, Kunio MINAMIZONO, Kosuke SASAKI, Takuya YOKOSAKA, Junji IGARASHI, Akinobu MARUYAMA, Hiroshi TAKAHASHI, Kyohei HORIE, Yuri SAKAI
  • THIENO- AND PYRROLOPYRIMIDINE ANALOGUES AS ANTICANCER AGENTS AND METHODS OF USE THEREOF
    Publication number: 20180161330
    Abstract: The present invention provides for the design and synthesis of halogenated thieno- and pyrrolopyrimidine compounds that exhibit cancer proliferation inhibitory activity and the use thereof for cancer treatment.
    Type: Application
    Filed: February 12, 2018
    Publication date: June 14, 2018
    Inventors: KATHERINE L. RADTKE, KARTIK TEMBURNIKAR
  • NOVEL TETRAHYDROPYRIDOPYRIMIDINE COMPOUND OR SALT THEREOF
    Publication number: 20180161331
    Abstract: A method for inhibiting androgen activity, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof, and a method for treating tumor, including administering an effective amount of a tetrahydropyridopyrimidine compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need thereof
    Type: Application
    Filed: February 12, 2018
    Publication date: June 14, 2018
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuhisa MINAMIGUCHI, Shigeo OKAJIMA, Shinichi AOKI, Masanori ASAI, Takahiro ASAI, Hiroyoshi YAMANAKA, Suguru DOHI
  • TREATMENT OF MITOCHONDRIAL DISEASES
    Publication number: 20180161332
    Abstract: The present invention provides a composition comprising one or more deoxyribonucleosides for use in the treatment of a mitochondrial DNA depletion and/or multiple deletions syndrome provided that the syndrome is not caused by a defect in the deoxyribonucleoside triphosphate (dNTP) metabolism. With the use of the invention there is a recovery in mitochondrial DNA levels independently from the severity of the patient's disease, which confers a great therapeutic value to the invention.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 14, 2018
    Inventors: Ramon MARTÍ SEVES, Emiliano GONZÁLEZ VIOQUE, Cora BLÁZQUEZ BERMEJO, Javier TORRES TORRONTERAS, Raquel CABRERA PÉREZ, Yolanda CÁMARA NAVARRO
  • INHIBITORS OF MACROPINOCYTOSIS IN PREVENTION AND TREATMENT OF DISEASE
    Publication number: 20180161333
    Abstract: Described herein are pharmaceutical compositions capable of inhibiting vesicle formation and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat pathogenic infections.
    Type: Application
    Filed: April 4, 2017
    Publication date: June 14, 2018
    Inventors: Robert Andrew Davey, Manu Anantpadma
  • USE OF FACTOR XA INHIBITORS FOR REGULATING GLYCEMIA
    Publication number: 20180161334
    Abstract: The present invention concerns a factor Xa inhibitor for use as a medicament in a method for regulating glycemia in a subject, in particular for use for preventing and/or treating hyperglycemia, impaired glucose tolerance, impaired fasting glucose, insulin resistance and/or diabetes.
    Type: Application
    Filed: April 8, 2016
    Publication date: June 14, 2018
    Inventors: Bérengère COUPÉ, Michael COURTNEY
  • METHODS TO TREAT NEUROLOGICAL DISEASES
    Publication number: 20180161335
    Abstract: Disclosed is a method of treating a subject who has a neurological disease. The neurological disease may be associated with altered C9ORF72 protein activity. In one aspect, the method includes a step of administering an effective dose of a pharmaceutical composition to a subject in need thereof, thereby rescuing the defects associated with altered C9ORF72 protein activity. Also described are methods for identifying a compound for inhibiting motor neuron degeneration.
    Type: Application
    Filed: June 24, 2016
    Publication date: June 14, 2018
    Inventors: Justin Ichida, Shaoyu Lin, Yichen Li, Yingxiao Shi
  • DNA-PK INHIBITORS
    Publication number: 20180161336
    Abstract: The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: July 25, 2017
    Publication date: June 14, 2018
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: John Patrick Maxwell, Paul S. Charifson, Qing Tang, Steven M. Ronkin, Katrina Lee Jackson, Albert Charles Pierce, David J. Lauffer, Pan Li, Simon Giroux, Jinwang Xu, Kevin Michael Cottrell, Mark A. Morris, Nathan D. Waal, John J. Court, Wenxin Gu, Hongbo Deng
  • NOVEL BICYCLIC BROMODOMAIN INHIBITORS
    Publication number: 20180161337
    Abstract: The invention relates to substituted bicyclic compounds, which are useful for inhibition of BET protein function by binding to bromodomains, pharmaceutical compositions comprising these compounds, and use of the compounds and compositions in therapy.
    Type: Application
    Filed: January 19, 2018
    Publication date: June 14, 2018
    Inventors: John Frederick QUINN, Bryan Cordell DUFFY, Shuang LIU, Ruifang WANG, May Xiaowu JIANG, Gregory Scott MARTIN, Gregory Steven WAGNER, Peter Ronald YOUNG
  • RETOSIBAN FOR THE TREATMENT OF PRE-TERM LABOUR
    Publication number: 20180161338
    Abstract: The present invention relates to a method of treating pre-term labour with retosiban in subjects with conditions resulting in uterine overdistension including polyhydroamnios and multiple gestation. In another aspect, the invention relates to a method of preventing pre-term labour in subjects by the prophylactic administration of retosiban.
    Type: Application
    Filed: February 8, 2018
    Publication date: June 14, 2018
    Inventor: Gordon Campbell Sinclair SMITH
  • USE OF CARBONIC ANHYDRASE INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
    Publication number: 20180161339
    Abstract: The invention is directed to the use of carbonic anhydrase inhibitors for treatment of neurological and psychiatric disorders.
    Type: Application
    Filed: July 21, 2017
    Publication date: June 14, 2018
    Applicant: New York University
    Inventor: Silvia Fossati
  • METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF HEARING LOSS
    Publication number: 20180161340
    Abstract: In one aspect, pharmaceutical compositions comprising a CDK2 inhibitor and one or more of at least one agent known to treat a hearing impairment and at least one agent known to prevent a hearing impairment, and methods of treating and/or preventing hearing impairments or disorders using the compositions are disclosed. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: June 20, 2016
    Publication date: June 14, 2018
    Inventors: Jian Zuo, Tai Teitz, Jie Fang, Asli Goktug, Taosheng Chen, Jaeki Min, R. Kiplin Guy
  • USE OF N-DESMETHYLCLOBAZAM IN THE TREATMENT OF CHRONIC PAIN DISORDERS AND RELATED METHODS
    Publication number: 20180161341
    Abstract: The present invention is directed to N-desmethylclobazam or any suitable pharmaceutically acceptable thereof useful for the prevention and/or treatment of a chronic pain disorder and related methods and pharmaceutical formulations.
    Type: Application
    Filed: March 2, 2016
    Publication date: June 14, 2018
    Inventors: JULES DESMEULES, HANNS ULRICH ZEILHOFER, MARIE BESSON, YOUSSEF DAALI, ALAIN MATTHEY, WILLIAM T. RALVENIUS
  • PROSTAMIDE-CONTAINING INTRAOCULAR IMPLANT
    Publication number: 20180161342
    Abstract: Prostamide-containing biodegradable intraocular implants, prostamide compounds, prostamide-containing pharmaceutical compositions, and methods for making and using such implants and compositions for the immediate and sustained reduction of intraocular pressure and treatment of glaucoma in an eye of a patient are described.
    Type: Application
    Filed: February 12, 2018
    Publication date: June 14, 2018
    Inventors: Patrick M. Hughes, Jie Shen, Michael R. Robinson, David F. Woodward, Robert M. Burk, Hui Liu, Jinping Wan, Chandrasekar Durairaj, Gyorgy F. Ambrus, Ke Wu, Danny T. Dinh
  • VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS
    Publication number: 20180161343
    Abstract: In one aspect, compositions and methods for the treatment of vulvovaginal atrophy (VVA) are provided. In one embodiment, the method comprises administering an estrogen to a subject having VVA by inserting a dosage form comprising a liquid pharmaceutical composition.
    Type: Application
    Filed: February 9, 2018
    Publication date: June 14, 2018
    Inventors: Sebastian Mirkin, Julia M. Amadio, Brian A. Bernick
  • VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS
    Publication number: 20180161344
    Abstract: In one aspect, compositions and methods for the treatment of vulvovaginal atrophy (VVA) are provided. In one embodiment, the method comprises administering an estrogen to a subject having VVA by inserting a dosage form comprising a liquid pharmaceutical composition.
    Type: Application
    Filed: February 9, 2018
    Publication date: June 14, 2018
    Inventors: Sebastian Mirkin, Julia M. Amadio, Brian A. Bernick
  • VAGINAL INSERTED ESTRADIOL PHARMACEUTICAL COMPOSITIONS AND METHODS
    Publication number: 20180161345
    Abstract: In one aspect, pharmaceutical compositions and methods for the treatment of vulvovaginal atrophy (VVA) are provided. In one embodiment, the method comprises digitally inserting into the lower third of the vagina of a subject having VVA a soft gelatin capsule containing a liquid pharmaceutical composition.
    Type: Application
    Filed: February 9, 2018
    Publication date: June 14, 2018
    Inventors: Brian A. Bernick, Thorsteinn Thorsteinsson, Peter H.R. Persicaner, Janice Louise Cacace, Frederick D. Sancilio
  • ESTRIOL THERAPY FOR TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20180161346
    Abstract: The present invention discloses administering steroid hormones to mammals to treat autoimmune related diseases, including post-partum auto immune diseases. Most preferably the invention uses estrogens, estranges, estriol or estrogen receptor active agents to prevent or ameliorate clinical symptoms of these Th1-mediated (cell-mediated) autoimmune diseases known to either have an initial onset following the birth of a child or which are exacerbated in patients in the post-partum period.
    Type: Application
    Filed: August 24, 2017
    Publication date: June 14, 2018
    Inventor: Rhonda R. Voskuhl
  • METHODS AND MATERIALS FOR KILLING HIV INFECTED CELLS
    Publication number: 20180161347
    Abstract: This document provides methods and materials involved in killing HIV infected cells (e.g., CD4 T cells). For example, methods and materials for using one or more Bcl-2 inhibitors (e.g., ABT-199) alone or in combination with one or more agents capable of reactivating HIV (e.g., latency reversing agent) to kill HIV infected cells (e.g., CD4 T cells) are provided.
    Type: Application
    Filed: April 20, 2016
    Publication date: June 14, 2018
    Applicant: Mayo Foundation for Medical Education and Research
    Inventors: Andrew D. Badley, Amy M. Nguyen, Scott H. Kaufmann, Yuan-Ping Pang, Haiming Dai
  • OSTEOCLAST INHIBITORS SUCH AS ZOLEDRONIC ACID FOR LOW BACK PAIN TREATMENT
    Publication number: 20180161348
    Abstract: Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as Modic changes type 1.
    Type: Application
    Filed: January 24, 2018
    Publication date: June 14, 2018
    Inventors: Herriot Tabuteau, Jaro I. Karppinen
  • ARGINASE INHIBITOR COMBINATION THERAPIES
    Publication number: 20180161349
    Abstract: The disclosure relates to methods of treating or preventing a disease in a subject by conjointly administering to the subject an arginase inhibitor disclosed herein and a composition comprising immune cells disclosed herein.
    Type: Application
    Filed: November 8, 2017
    Publication date: June 14, 2018
    Inventors: Amani MAKKOUK, Matthew I. GROSS, Francesco PARLATI
  • TERNARY MIXTURES OF 6'-SL, LNnT and LST c
    Publication number: 20180161350
    Abstract: A mixture of human milk oligosaccharides that consists essentially of 6?-SL, LNnT and LSTc, made by treating 6?-SL and LNnT in the presence of an ?2,6-transsialidase.
    Type: Application
    Filed: June 9, 2016
    Publication date: June 14, 2018
    Inventors: Elise CHAMPION, Bruce MCCONNELL, Gyula DEKANY
  • NUTRITIONAL FORMULATIONS INCLUDING HUMAN MILK OLIGOSACCHARIDES AND ANTIOXIDANTS AND USES THEREOF
    Publication number: 20180161351
    Abstract: Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
    Type: Application
    Filed: February 8, 2018
    Publication date: June 14, 2018
    Applicant: ABBOTT LABORATORIES
    Inventors: RACHAEL BUCK, GERALYN O. DUSKA-MCEWEN, JOSEPH P. SCHALLER
  • NUTRITIONAL FORMULATIONS INCLUDING HUMAN MILK OLIGOSACCHARIDES AND ANTIOXIDANTS AND USES THEREOF
    Publication number: 20180161352
    Abstract: Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
    Type: Application
    Filed: February 8, 2018
    Publication date: June 14, 2018
    Applicant: ABBOTT LABORATORIES
    Inventors: RACHAEL BUCK, GERALYN O. DUSKA-MCEWEN, JOSEPH P. SCHALLER
  • NUTRITIONAL FORMULATIONS INCLUDING HUMAN MILK OLIGOSACCHARIDES AND ANTIOXIDANTS AND USES THEREOF
    Publication number: 20180161353
    Abstract: Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
    Type: Application
    Filed: February 9, 2018
    Publication date: June 14, 2018
    Applicant: ABBOTT LABORATORIES
    Inventors: RACHAEL BUCK, GERALYN O. DUSKA-MCEWEN, JOSEPH P. SCHALLER
  • NUTRITIONAL FORMULATIONS INCLUDING HUMAN MILK OLIGOSACCHARIDES AND ANTIOXIDANTS AND USES THEREOF
    Publication number: 20180161354
    Abstract: Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
    Type: Application
    Filed: February 9, 2018
    Publication date: June 14, 2018
    Applicant: ABBOTT LABORATORIES
    Inventors: RACHAEL BUCK, GERALYN O. DUSKA-MCEWEN, JOSEPH P. SCHALLER
  • Method For Storing P1, P4-bis(5'-Uridyl)Tetraphosphate Crystals
    Publication number: 20180161355
    Abstract: [Problem] Provided is a method for easily and stably storing crystals of P1, P4-bis(5?-uridyl)tetraphosphate for a long term. [Solution] A method for storing packed crystals of P1, P4-bis(5?-uridyl)tetraphosphate or a pharmaceutically acceptable salt thereof, wherein one of the following storage conditions (1) to (3): (1) a storage temperature of 0° C. or more and less than 25° C.; (2) a storage temperature of 25° C. or more and less than 40° C. and a crystal pH of 4.5 to 8.0; and (3) a storage temperature of 40° C. or more and less than 60° C. and a crystal pH of 5.0 to 6.4 is selected and the crystals of P1, P4-bis (5?-uridyl) tetraphosphate or the pharmaceutically acceptable salt thereof are stored under the selected condition.
    Type: Application
    Filed: June 28, 2016
    Publication date: June 14, 2018
    Applicant: Yamasa Corporation
    Inventors: Yusuke OHBA, Kentaro MIYOSHI, Fumitaka KANO
  • TAU ANTISENSE OLIGOMERS AND USES THEREOF
    Publication number: 20180161356
    Abstract: The present invention relates to oligomer compounds (oligomers), which target Tau mRNA in a cell, leading to reduced expression of Tau protein. Reduction of Tau protein expression is beneficial for the treatment of certain medical disorders, e.g., a neurological disorder.
    Type: Application
    Filed: February 4, 2016
    Publication date: June 14, 2018
    Inventors: Richard E. Olson, Angela M. Cacace, Peter Hagedorn, Anja Mølhart Høg, Marianne Lerbech Jensen, Niels Fisker Nielsen, Dong Li, Jeffrey M. Brown, Stephen E. Mercer
  • MIR-155 INHIBITORS FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    Publication number: 20180161357
    Abstract: The present invention provides methods for treating a neurological disease such as ALS in a subject by administering to the subject an oligonucleotide inhibitor of miR-155. The invention also provides methods for treating neuroinflammation by administering an oligonucleotide inhibitor of miR-155.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 14, 2018
    Inventors: Aimee JACKSON, Christina DALBY, Howard L. WEINER, Oleg BUTOVSKY
  • COMPOSITIONS AND METHODS FOR TREATING CANCER
    Publication number: 20180161358
    Abstract: Provided are nucleic acid constructs and systems which comprise (i) a first nucleic acid construct encoding a toxin operatively linked to a first promoter and at least one cancer-associated signaling responsive enhancer element; and (ii) a second nucleic acid construct encoding an anti-toxin operatively linked to a second promoter, the second promoter being stronger than the first promoter. Also provided are pharmaceutical compositions comprising same and methods of using same for treating cancer.
    Type: Application
    Filed: May 17, 2016
    Publication date: June 14, 2018
    Inventors: Nadir ARBER, Shiran SHAPIRA, Dina KAZANOV
  • METHODS AND COMPOUNDS FOR TREATMENT OF LYMPHOCYTE-RELATED DISEASES AND CONDITIONS
    Publication number: 20180161359
    Abstract: Methods for treatment of lymphocyte-related diseases and conditions, such as cancer and automimmune diseases, are provided. The methods comprise administration of an effective amount of an oligomer to a patient in need thereof, wherein the oligomer comprises, inter alia, at least one intersubunit linkage having the following structure: wherein R1, L1, X, Y and Z are as defined herein.
    Type: Application
    Filed: June 3, 2016
    Publication date: June 14, 2018
    Inventors: Dan V. Mourich, Gunnar J. Hanson, Frederick Joseph Schnell, Johannes Christian Dworzak